摘要:
The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
摘要:
The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
摘要:
The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
摘要:
The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.
摘要:
Compositions comprising a novel protease capable of cleaving β-amyloid precursor protein (APP) on the amino-terminal side of the β-amyloid peptide therein are provided. The protease is designated β-secretase. Reaction systems comprising β-secretase may be used in screening assays to monitor β-secretase modulated cleavage of APP and to identify β-secretase inhibitors, wherein the β-secretase is in the presence of a suitable polypeptide substrate and cleavage of the substrate determined in the presence and absence of the test substance. Antibodies are raised against peptides of β-secretase. Pharmaceutical compositions and methods comprise compounds identified by screening assays.
摘要:
The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.
摘要:
Compositions comprising a novel protease capable of cleaving &bgr;-amyloid precursor protein (APP) on the amino-terminal side of the &bgr;-amyloid peptide therein are provided. The protease is designated &bgr;-secretase. Reaction systems comprising &bgr;-secretase may be used in screening assays to monitor &bgr;-secretase modulated cleavage of APP and to identify &bgr;-secretase inhibitors, wherein the &bgr;-secretase is in the presence of a suitable polypeptide substrate and cleavage of the substrate determined in the presence and absence of the test substance. Antibodies are raised against peptides of &bgr;-secretase. Pharmaceutical compositions and methods comprise compounds identified by screening assays.
摘要:
Compositions comprising a novel protease capable of cleaving .beta.-amyloid precursor protein (APP) on the amino-terminal side of the .beta.-amyloid peptide therein are provided. The protease is designated .beta.-secretase. Reaction systems comprising .beta.-secretase may be used in screening assays to monitor .beta.-secretase modulated cleavage of APP and to identify .beta.-secretase inhibitors, wherein the .beta.-secretase is in the presence of a suitable polypeptide substrate and cleavage of the substrate determined in the presence and absence of the test substance. Antibodies are raised against peptides of .beta.-secretase. Pharmaceutical compositions and methods comprise compounds identified by screening assays.
摘要:
A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the .beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.
摘要:
A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the .beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.